Thyme Care: Fixing Value-Based Care’s Challenges

The pursuit of value-based care in oncology – a system aiming to improve patient outcomes whereas controlling costs – has faced significant headwinds. But one company, Thyme Care, is demonstrating a different trajectory. Founded in 2020, Thyme Care isn’t simply tweaking the existing model; it’s building a comprehensive, tech-enabled system that proactively navigates patients through the complexities of a cancer diagnosis and treatment, and is now expanding its reach with $95 million in modern funding. This approach, which assumes financial risk tied to both cost and quality, appears to be addressing some of the core reasons why broader value-based care initiatives have struggled to gain traction.

Navigating a Fragmented System

Cancer care is notoriously fragmented. Patients often encounter a maze of appointments, tests, and specialists, with limited coordination. This can lead to delays in diagnosis, suboptimal treatment decisions, and increased anxiety for patients and their families. Thyme Care steps in as a dedicated oncology care team, providing 24/7 virtual support and proactively managing symptoms. They connect patients with essential resources like transportation assistance and help navigating billing issues – practical hurdles that can significantly impact a patient’s ability to adhere to their care plan. The company partners with health plans, employers, and risk-bearing providers to streamline this process.

A key differentiator for Thyme Care is its universal approach. Unlike many value-based care programs that target specific populations or geographic areas, Thyme Care works with all patients within a given payer network, regardless of where they receive treatment or which physician they notice. As reported in AJMC, this broad inclusivity is a critical element of their success. This contrasts with traditional value-based care models that can be limited by provider networks or geographic constraints.

Aligning Incentives Through Risk-Sharing

One of the biggest challenges with value-based care is aligning the financial incentives of all stakeholders. Traditionally, healthcare providers are paid for volume – the more services they provide, the more they earn. This can discourage preventative care and coordinated care, which are essential for improving outcomes and reducing costs. Thyme Care addresses this by assuming two-sided financial risk. Which means they share in the savings generated by providing high-quality, cost-effective care, but also bear the financial consequences if costs exceed expectations. This model incentivizes them to focus on delivering the right care at the right time, rather than simply maximizing the number of services provided.

This risk-sharing arrangement is coupled with a hybrid collaborative care model. Thyme Care integrates with over 800 oncologists through its Thyme Care Oncology Partners network, functioning as an extension of the existing clinical team. This isn’t about replacing oncologists; it’s about augmenting their capabilities with dedicated care navigation and support services. According to Fierce Healthcare, the company currently manages 10,000 patients, a number projected to triple in 2025.

The Role of Technology and Data Insights

Thyme Care’s approach isn’t solely reliant on human interaction. The company leverages technology and data insights to enhance its care navigation services. This includes using data analytics to identify patients who are at high risk of complications or who may benefit from additional support. The tech-enabled care team can then proactively reach out to these patients and provide personalized guidance. This proactive approach is a departure from traditional reactive care models, where patients typically only receive support when they encounter a problem.

The company’s platform also facilitates communication and coordination among different members of the care team, ensuring that everyone is on the same page. What we have is particularly important in cancer care, where patients often have multiple specialists involved in their treatment. As outlined on the Thyme Care website, their services aim to improve access, experience, and costs for cancer patients.

Expanding Reach and Impact

The recent $95 million funding round will enable Thyme Care to expand its services into new markets and forge partnerships with more oncology and primary care practices, as well as health plans. Currently, the company serves patients in 31 states. This expansion is crucial for addressing the widespread challenges of cancer care access, and affordability. Brad Diephuis, president and chief operating officer of Thyme Care, indicated that the funding will support infrastructure development to replicate their success in existing markets and scale into new ones.

Addressing the Limitations of Traditional Value-Based Care

Traditional value-based care models often struggle with complexity and a lack of standardization. Defining “value” in healthcare is inherently difficult, and measuring outcomes can be challenging. Thyme Care’s focused approach – specifically targeting cancer care navigation – allows them to overcome some of these hurdles. By concentrating on a specific disease state, they can develop standardized protocols and metrics for measuring success. Their assumption of financial risk incentivizes them to deliver measurable results.

It’s important to note that Thyme Care’s model is not without its potential limitations. The success of their approach may depend on the willingness of health plans and providers to embrace risk-sharing arrangements. The company’s reliance on technology and data analytics raises concerns about data privacy and security. Still, these are challenges that are common to many innovative healthcare companies, and Thyme Care appears to be taking steps to address them.

Looking Ahead: Continued Growth and Refinement

The future of Thyme Care hinges on its ability to demonstrate sustained improvements in patient outcomes and cost savings. Continued monitoring of their performance data will be essential for validating their model and identifying areas for improvement. Further research is needed to understand the long-term impact of their approach on cancer survival rates and quality of life. As the company expands into new markets, it will be crucial to adapt its services to meet the unique needs of different patient populations. The company’s commitment to data-driven decision-making and collaborative partnerships positions it well for continued growth and success in the evolving landscape of cancer care.